机构:[1]Guangzhou Univ Chinese Med, Sch Pharmaceut Sci, Guangzhou 510006, Peoples R China[2]Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou 510120, Peoples R China广东省中医院[3]Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangzhou 510120, Peoples R China广东省中医院[4]Guangdong Prov Hosp Chinese Med, Li Ke & Qi Yu ru Acad Experience Inheritance Studi, Guangzhou 510006, Peoples R China广东省中医院[5]Guangzhou Univ Chinese Med, State Key Lab Dampness Syndrome Chinese Med, Affiliated Hosp 2, Guangzhou 510120, Peoples R China广东省中医院[6]Guangdong Prov Key Lab Clin Res Tradit Chinese Med, Guangzhou 510120, Peoples R China广东省中医院
Purpose: Gouty arthritis could be triggered by the deposition of monosodium uric acid (MSU) crystals. Palmatine (PAL), a protoberberine alkaloid, has been proven to possess compelling health-beneficial activities. In this study, we aimed to explore the effect of PAL on LPS plus MSU crystal-stimulated gouty arthritis in vitro and in vivo.Methods: PMA-differentiated THP-1 macrophages were primed with LPS and then stimulated with MSU crystal in the presence or absence of PAL. The expression of pro-inflammatory cytokines and oxidative stress-related biomarkers and signal pathway key targets were determined by ELISA kit, Western blot, immunohistochemistry and qRT-PCR, respectively. In addition, the anti-inflammatory and antioxidant activities of PAL on MSU-induced arthritis mice were also evaluated.Results: The results indicated that PAL (20, 40 and 80 mu M) dose-dependently decreased the mRNA expression and levels of pro-inflammatory cytokines (interleukin-1beta (IL-1 beta), IL-6, IL-18 and tumor necrosis factor alpha (TNF-alpha)). The levels of superoxide dismutase (SOD) and glutathione (GSH) were remarkably enhanced, while the level of malondialdehyde (MDA) was reduced. Western blot analysis revealed that PAL appreciably inhibited NF-Kappa B/NLRP3 signaling pathways through inhibiting the phosphorylation of p-65 and I Kappa B alpha, blocking the expression of NLRP3, ASC, IL-1 beta and Caspase-1, as well as enhancing the antioxidant protein expression of Nrf2 and HO-1. In vivo, PAL attenuated MSUinduced inflammation in gouty arthritis, as evidenced by mitigating the joint swelling, and decreasing the productions of IL-1 beta, IL-6, IL-18, TNF-alpha and MDA, while enhancing the levels of SOD and GSH. Moreover, PAL further attenuated the infiltration of neutrophils into joint synovitis. Conclusion: PAL protected against MSU-induced inflammation and oxidative stress via regulating the NF-Kappa B/NLRP3 and Nrf2 pathways. PAL may represent a potential candidate for the treatment of gouty arthritis.
基金:
National Natural Science Foundation of China [82074082, 82104472]; Guangdong Natural Science Foundation [2021A1515011490, 2019A1515010819, 2022A1515011706]; Characteristic Cultivation Program for Subject Research of Guangzhou University of Chinese Medicine [XKP2019007]; Guangzhou Liwan Disrtrict Science and Technology Project [202201005]; Key Program for Subject Research of Guangzhou University of Chinese Medicine [XK2019002]; Chinese Medicine Bureau of Guangdong Province [20201134]
第一作者机构:[1]Guangzhou Univ Chinese Med, Sch Pharmaceut Sci, Guangzhou 510006, Peoples R China
通讯作者:
通讯机构:[3]Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangzhou 510120, Peoples R China[4]Guangdong Prov Hosp Chinese Med, Li Ke & Qi Yu ru Acad Experience Inheritance Studi, Guangzhou 510006, Peoples R China
推荐引用方式(GB/T 7714):
Cheng Juan -Juan,Ma Xing-Dong,Ai Gao-Xiang,et al.Palmatine Protects Against MSU-Induced Gouty Arthritis via Regulating the NF-?B/NLRP3 and Nrf2 Pathways[J].DRUG DESIGN DEVELOPMENT AND THERAPY.2022,16:2119-2132.doi:10.2147/DDDT.S356307.
APA:
Cheng, Juan -Juan,Ma, Xing-Dong,Ai, Gao-Xiang,Yu, Qiu-Xia,Chen, Xiao-Ying...&Xie, Qing-Feng.(2022).Palmatine Protects Against MSU-Induced Gouty Arthritis via Regulating the NF-?B/NLRP3 and Nrf2 Pathways.DRUG DESIGN DEVELOPMENT AND THERAPY,16,
MLA:
Cheng, Juan -Juan,et al."Palmatine Protects Against MSU-Induced Gouty Arthritis via Regulating the NF-?B/NLRP3 and Nrf2 Pathways".DRUG DESIGN DEVELOPMENT AND THERAPY 16.(2022):2119-2132